AtriCure Management
Management criteria checks 2/4
AtriCure's CEO is Mike Carrel, appointed in Nov 2012, has a tenure of 12.08 years. total yearly compensation is $8.75M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 1.36% of the company’s shares, worth $19.86M. The average tenure of the management team and the board of directors is 7.8 years and 7.8 years respectively.
Key information
Mike Carrel
Chief executive officer
US$8.7m
Total compensation
| CEO salary percentage | 9.2% |
| CEO tenure | 12.1yrs |
| CEO ownership | 1.4% |
| Management average tenure | 7.8yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb
Nov 06
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
Nov 01Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
Oct 31AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price
Oct 02Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce
Sep 06Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
Aug 02AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care
Jul 25AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward
Jul 18AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price
May 30Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump
Apr 04Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Mar 14Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues
Jan 21Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Nov 29AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Sep 27Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?
Aug 02AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion
Jun 15Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
Apr 14Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)
Mar 02What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?
Feb 09Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Dec 28Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?
Sep 06An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued
Aug 02AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks
Jun 13Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
Jun 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$39m |
| Jun 30 2024 | n/a | n/a | -US$40m |
| Mar 31 2024 | n/a | n/a | -US$37m |
| Dec 31 2023 | US$9m | US$804k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$28m |
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | US$8m | US$795k | -US$46m |
| Sep 30 2022 | n/a | n/a | -US$56m |
| Jun 30 2022 | n/a | n/a | US$53m |
| Mar 31 2022 | n/a | n/a | US$52m |
| Dec 31 2021 | US$8m | US$766k | US$50m |
| Sep 30 2021 | n/a | n/a | US$45m |
| Jun 30 2021 | n/a | n/a | -US$57m |
| Mar 31 2021 | n/a | n/a | -US$49m |
| Dec 31 2020 | US$6m | US$718k | -US$48m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$50m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$6m | US$740k | -US$35m |
| Sep 30 2019 | n/a | n/a | -US$23m |
| Jun 30 2019 | n/a | n/a | -US$20m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | US$4m | US$714k | -US$21m |
| Sep 30 2018 | n/a | n/a | -US$20m |
| Jun 30 2018 | n/a | n/a | -US$20m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$4m | US$671k | -US$27m |
Compensation vs Market: Mike's total compensation ($USD8.75M) is above average for companies of similar size in the US market ($USD5.51M).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
CEO
Mike Carrel (53 yo)
12.1yrs
Tenure
US$8,749,289
Compensation
Mr. Michael H. Carrel, also known as Mike, serves as the Chief Executive Officer and President at AtriCure, Inc. since November 2012. Mr. Carrel has been Director at Axonics Inc. since February 27, 2019 an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 12.1yrs | US$8.75m | 1.36% $ 19.9m | |
| Chief Financial Officer | 4.3yrs | US$2.92m | 0.29% $ 4.2m | |
| Chief Operating Officer | 9.9yrs | US$3.50m | 0.32% $ 4.6m | |
| Chief Technical Officer | 7.9yrs | US$2.13m | 0.21% $ 3.1m | |
| Chief Legal Officer | 5.8yrs | US$2.13m | 0.11% $ 1.6m | |
| Chief Scientific Officer | 7.8yrs | US$1.78m | 0.12% $ 1.8m | |
| Vice President of Corporate Marketing & Communications | no data | no data | no data | |
| Chief Marketing & Strategy Officer | 8.8yrs | US$1.78m | 0.15% $ 2.1m | |
| Chief Human Resources Officer | 2.5yrs | US$1.92m | 0.098% $ 1.4m |
7.8yrs
Average Tenure
53.5yo
Average Age
Experienced Management: ATRC's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 12.1yrs | US$8.75m | 1.36% $ 19.9m | |
| Independent Director | 8.1yrs | US$227.47k | 0.059% $ 870.7k | |
| Independent Director | 7.8yrs | US$264.97k | 0.091% $ 1.3m | |
| Independent Director | less than a year | no data | 0.027% $ 393.9k | |
| Independent Chairman of the Board | 11.8yrs | US$225.47k | 0.20% $ 2.9m | |
| Independent Director | 5yrs | US$219.97k | 0.049% $ 719.0k | |
| Independent Director | 3.5yrs | US$209.97k | 0.018% $ 269.6k | |
| Independent Director | 7.8yrs | US$232.47k | 0.063% $ 924.6k | |
| Independent Director | 3.5yrs | US$212.47k | 0.034% $ 504.3k |
7.8yrs
Average Tenure
62yo
Average Age
Experienced Board: ATRC's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 02:08 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AtriCure, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Joanne Wuensch | BMO Capital Markets U.S. (Historical) |
| Michael Gorman | BTIG |